Subunit respiratory syncytial virus vaccine preparation
AssigneeConnaught Laboratories Limited
InventorsGeorge A. Cates, Sonia E. Sanhueza, Raymond P. Oomen, Michel H. Klein
Life of this patent
Estimating the term…
Abstract
The fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV) are isolated and purified from respiratory syncytial virus by mild detergent extraction of the proteins from concentrated virus, loading the protein onto a hydroxyapatite or other ion-exchange matrix column and eluting the protein using mild salt treatment. The F, G and M proteins, formulated as immunogenic compositions, are safe and highly immunogenic and protect relevant animal models against respiratory syncytial virus.
Claims15
A mixture of purified fusion protein (F), attachment protein (G) and matrix (M) protein of respiratory syncytial virus in the relative proportions of:
- F from about 40 to about 70 wt %
- G from about 5 to about 20 wt %
- M from about 20 to about 40 wt %.
A mixture consisting essentially of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV).
A coisolated and copurified mixture of non-denatured proteins of respiratory syncytial virus (RSV), consisting essentially of the fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV, wherein the mixture is free from lectins and is free from monoclonal antibodies.
Dependencies are inferred from the claim text.